Adverse events190

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

1 to 20 of 190

Type	Event	Organ system	Group	Affected	At risk	Events
other	Anaemia	Blood and lymphatic system disorders	CD30 <1% [Local Laboratory Assessment]	7	34	7
other	Anaemia	Blood and lymphatic system disorders	CD30 1% to <10% [Local Laboratory Assessment]	15	48	18
other	Febrile neutropenia	Blood and lymphatic system disorders	CD30 <1% [Local Laboratory Assessment]	2	34	2
other	Febrile neutropenia	Blood and lymphatic system disorders	CD30 1% to <10% [Local Laboratory Assessment]	1	48	1
other	Lymphopenia	Blood and lymphatic system disorders	CD30 <1% [Local Laboratory Assessment]	1	34	1
other	Lymphopenia	Blood and lymphatic system disorders	CD30 1% to <10% [Local Laboratory Assessment]	5	48	6
other	Neutropenia	Blood and lymphatic system disorders	CD30 <1% [Local Laboratory Assessment]	4	34	4
other	Neutropenia	Blood and lymphatic system disorders	CD30 1% to <10% [Local Laboratory Assessment]	12	48	19
other	Thrombocytopenia	Blood and lymphatic system disorders	CD30 <1% [Local Laboratory Assessment]	0	34	0
other	Thrombocytopenia	Blood and lymphatic system disorders	CD30 1% to <10% [Local Laboratory Assessment]	5	48	5
other	Abdominal pain	Gastrointestinal disorders	CD30 <1% [Local Laboratory Assessment]	2	34	2
other	Abdominal pain	Gastrointestinal disorders	CD30 1% to <10% [Local Laboratory Assessment]	4	48	4
other	Constipation	Gastrointestinal disorders	CD30 <1% [Local Laboratory Assessment]	3	34	3
other	Constipation	Gastrointestinal disorders	CD30 1% to <10% [Local Laboratory Assessment]	7	48	7
other	Diarrhoea	Gastrointestinal disorders	CD30 <1% [Local Laboratory Assessment]	6	34	9
other	Diarrhoea	Gastrointestinal disorders	CD30 1% to <10% [Local Laboratory Assessment]	19	48	25
other	Gastrooesophageal reflux disease	Gastrointestinal disorders	CD30 <1% [Local Laboratory Assessment]	0	34	0
other	Gastrooesophageal reflux disease	Gastrointestinal disorders	CD30 1% to <10% [Local Laboratory Assessment]	3	48	3
other	Nausea	Gastrointestinal disorders	CD30 <1% [Local Laboratory Assessment]	8	34	11
other	Nausea	Gastrointestinal disorders	CD30 1% to <10% [Local Laboratory Assessment]	14	48	21

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT04569032/events

API reference For AI assistants

Adverse events190

Sources 3

Read this list from software.